Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Various translocations and mutations have been identified in myeloma, and certain aberrations, such as t(4;14) and del17, are linked with disease prognosis. To investigate mutational prevalence in myeloma and associations between mutations and patient outcomes, we tested a panel of 41 known oncogene...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Mulligan, George, Lichter, David I., Di Bacco, Alessandra, Blakemore, Stephen J., Berger, Allison, Koenig, Erik, Bernard, Hugues, Trepicchio, William, Li, Bin, Neuwirth, Rachel, Chattopadhyay, Nibedita, Bolen, Joseph B., Dorner, Andrew J., van de Velde, Helgi, Ricci, Deborah, Jagannath, Sundar, Berenson, James R., Richardson, Paul G., Stadtmauer, Edward A., Orlowski, Robert Z., Lonial, Sagar, Anderson, Kenneth C., Sonneveld, Pieter, San Miguel, Jesús F., Esseltine, Dixie-Lee, Schu, Matthew
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2014
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123425/
https://ncbi.nlm.nih.gov/pubmed/24335104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-05-504340
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia